P-01
Lead cardiac myosin inhibitor
Indication · Non-obstructive HCMDiscoveryPhase 1Phase 2Phase 3Review
Positive Phase 2
Positive Phase 2 results reported in non-obstructive HCM.
Home / Pipeline
03 · Pipeline
One compound, advancing across the disease.
A single lead cardiac myosin inhibitor, carried with rigour across both forms of HCM and into global, late-stage development.
The programme
Singular by intention.
EYEAM's pipeline is deliberately narrow. It is one lead cardiac myosin inhibitor, pursued across both major forms of hypertrophic cardiomyopathy and into global, late-stage clinical development. Mid-stage results have been positive in each form, and the programme now advances toward the people it is meant to reach.
P-02
Lead cardiac myosin inhibitor
Indication · Obstructive HCMDiscoveryPhase 1Phase 2Phase 3Review
Positive Phase 2
Positive Phase 2 results, reported alongside a pharmaceutical partner and including international clinical data.
P-03
Lead cardiac myosin inhibitor
Programme · Global late-stage developmentDiscoveryPhase 1Phase 2Phase 3Review
Advancing
Advancing through global, late-stage clinical development toward potential regulatory submission.
Positive Phase 2 results across both the obstructive and non-obstructive forms underpin EYEAM's continued investment in advancing this single programme. EYEAM's lead candidate is investigational and has not been approved by any regulatory authority for any use.
How development works
The path a medicine travels.
Clinical development moves in stages, each answering a sharper question than the one before it, with the evidence building as it goes.
Phase 1
Safety and handling
First studies in people, focused on how a candidate is tolerated and how the body processes it, usually in a small group.
Phase 2
Effect and dose
Studies in people living with the condition, testing whether the candidate works as intended and helping define the right dose.
Phase 3
Confirmatory evidence
Larger, late-stage studies that gather the confirmatory data regulators weigh when considering approval.
Review
Regulatory decision
Authorities assess the full body of evidence to decide whether a medicine can be made available, and to whom.
Late-stage development
What advancing toward patients asks of us.
Phase 2 tells you a candidate can work. Phase 3 is where you find out how well, in whom, and how reliably, at the scale and rigour that a regulatory decision requires. It is the most demanding part of the journey, and the part closest to the people the medicine is for.
Reaching that scale is not something a focused company does alone. EYEAM advances its programme through international clinical development and external collaboration, drawing on partners and investigators who share the goal of bringing a mechanism-directed therapy to a defined community of patients.
The last stretch is the hardest, and the one that matters most.
Both formsPositive Phase 2 in obstructive and non-obstructive HCM, the evidence that anchors the programme.
ScaleGlobal, late-stage development, gathering the confirmatory evidence approval depends on.
CollaborationExternal partnership and international investigators extend the reach of a focused team.
DestinationPotential submission to regulators, and the patients a decision would serve.
A note on what these terms mean.
Positive Phase 2 results describe a candidate that has met the goals of its mid-stage studies. They are an important signal, not a conclusion. A medicine is not approved, and cannot be prescribed, until it has completed the confirmatory late-stage studies and been reviewed and cleared by the relevant regulatory authorities. EYEAM's lead candidate remains investigational, and nothing on this page should be read as a claim of approval, efficacy or availability.
Work with us
A programme moves on people.
Investigators, partners, investors and prospective colleagues who want to help carry this work forward are all welcome to reach out.